181 related articles for article (PubMed ID: 23463593)
1. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Fleitas T; Martínez-Sales V; Vila V; Reganon E; Mesado D; Martín M; Gómez-Codina J; Montalar J; Reynés G
Clin Transl Oncol; 2013 Nov; 15(11):897-902. PubMed ID: 23463593
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T
Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231
[TBL] [Abstract][Full Text] [Related]
3. Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy.
An SJ; Huang YS; Chen ZH; Su J; Yang Y; Chen JG; Yan HH; Lin QX; Yang JJ; Yang XN; Zhou Q; Zhang XC; Wu YL
Med Oncol; 2012 Jun; 29(2):627-32. PubMed ID: 21461966
[TBL] [Abstract][Full Text] [Related]
4. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Edelman MJ; Hodgson L; Wang X; Christenson R; Jewell S; Vokes E; Kratzke R
J Thorac Oncol; 2011 Nov; 6(11):1902-6. PubMed ID: 21964530
[TBL] [Abstract][Full Text] [Related]
5. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Correale P; Remondo C; Carbone SF; Ricci V; Migali C; Martellucci I; Licchetta A; Addeo R; Volterrani L; Gotti G; Rotundo MS; Tassone P; Sperlongano P; Abbruzzese A; Caraglia M; Tagliaferri P; Francini G
Cancer Biol Ther; 2010 May; 9(9):685-93. PubMed ID: 20697196
[TBL] [Abstract][Full Text] [Related]
6. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
10. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Mok T; Gorbunova V; Juhasz E; Szima B; Burdaeva O; Orlov S; Yu CJ; Archer V; Hilton M; Delmar P; Pallaud C; Reck M
J Thorac Oncol; 2014 Jun; 9(6):848-55. PubMed ID: 24807156
[TBL] [Abstract][Full Text] [Related]
11. The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
Fidler MJ; Fhied CL; Roder J; Basu S; Sayidine S; Fughhi I; Pool M; Batus M; Bonomi P; Borgia JA
BMC Cancer; 2018 Mar; 18(1):310. PubMed ID: 29558888
[TBL] [Abstract][Full Text] [Related]
12. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
Michelsen L; Sørensen JB
Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
[TBL] [Abstract][Full Text] [Related]
13. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival.
Nisman B; Biran H; Heching N; Barak V; Ramu N; Nemirovsky I; Peretz T
Br J Cancer; 2008 Jan; 98(1):77-9. PubMed ID: 18087272
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
[TBL] [Abstract][Full Text] [Related]
16. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
Hoang T; Dahlberg SE; Sandler AB; Brahmer JR; Schiller JH; Johnson DH
J Thorac Oncol; 2012 Sep; 7(9):1361-8. PubMed ID: 22843087
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group.
Tanriverdi O; Avci N; Oktay E; Kalemci S; Pilanci KN; Cokmert S; Menekse S; Kocar M; Sen CA; Akman T; Ordu C; Goksel G; Meydan N; Barutca S
Asian Pac J Cancer Prev; 2015; 16(14):5971-6. PubMed ID: 26320482
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
19. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
20. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
